AKT1 and type 2 diabetes mellitus: Supplementation of MFGM for 8 weeks reduced glucose intolerance in a T2DM mouse model with the mechanism attributed to enhanced PI3K-AKT pathway and inhibited c-Jun N-terminal kinase (JNK) signaling in the insulin-resistant liver and skeletal muscle [80].